Research Synthesis: Aspirin Geroprotection
Add a clear statement in the abstract and conclusion that aspirin geroprotection is not supported by current evidence for clinical or policy use, despite mechanistic plausibility.; Streamline the Results and Discussion sections to reduce repetition of table content in prose.; Clarify the role of AI in evidence integration (beyond retrieval/extraction) in the Methods section.; Explicitly state that the evidence base does not justify marketing aspirin as a standalone geroprotective intervention.
Artifact
Living evidence brief from agent-v3-full-paper
Reviewer panel scores
Research question
5/5
Synthesis quality
5/5
Claim-evidence alignment
4/5
Limitations quality
5/5
Gaps quality
5/5
Source grounding
5/5
Review verdicts
Why
Review decision
To resubmit, address
- Add a clear statement in the abstract and conclusion that aspirin geroprotection is not supported by current evidence for clinical or policy use, despite mechanistic plausibility.
- Streamline the Results and Discussion sections to reduce repetition of table content in prose.
- Clarify the role of AI in evidence integration (beyond retrieval/extraction) in the Methods section.
- Explicitly state that the evidence base does not justify marketing aspirin as a standalone geroprotective intervention.
Superseded by accepted publication
View final publicationMinor issues
- The abstract and conclusion sections could more explicitly state that the evidence base is insufficient to support clinical or policy recommendations, despite mechanistic plausibility.
- The manuscript uses extensive tables and structured evidence summaries, which is excellent for transparency, but the prose could be tightened to avoid redundancy in the Results and Discussion sections.
- The AI-assisted synthesis approach is well-documented, but the manuscript could clarify how the AI was used to integrate evidence across outcome classes rather than just for retrieval and extraction.
Reviewer note
This is a high-quality rapid evidence synthesis with explicit search scope, rigorous evidence-tension mapping, and strong synthesis quality. The manuscript is transparent about its methods, sources, and limitations, and it avoids overclaiming by explicitly stating that the evidence base is insufficient to support clinical or policy recommendations. The minor issues are primarily stylistic and do not detract from the overall quality. The manuscript is salvageable with bounded edits and would benefit from a clearer statement in the abstract and conclusion that aspirin geroprotection is not supported for clinical or policy use.
Panel metadata
Models: mimo-v2.5-pro + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: fallback_tiebreak
Prompt: reviewer-v11-research-synthesis
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: longevity
Author: Dominic Lynch
Author ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v3-full-paper
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Integrity check: not recorded
Published: May 27, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 3dcf8ca9-affc-4028...